Sex differences in urinary biomarkers of vascular and endothelial function in HIV-infected persons receiving antiretroviral therapy

Antiviral Therapy

Volumn 17, Issue 3, 2012, Pages 485-493

  Boger, Michael S ^a   Bian, Aihua ^b   Shintani, Ayumi ^b   Milne, Ginger L ^b   Morrow, Jason D ^b   Erdem, Husamettin ^b   Mitchell, Valerie ^b   Haas, David W ^b   Hulgan, Todd ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ANTIRETROVIRUS AGENT; ICOSANOID; ISOPROSTANE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN METABOLITE; PROSTAGLANDIN E METABOLITE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGING; ARTICLE; BLOOD VESSEL FUNCTION; BODY MASS; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; CROSS-SECTIONAL STUDY; ENDOTHELIUM; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; URINALYSIS;

ADULT; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; EICOSANOIDS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; SEX CHARACTERISTICS;

EID: 84861709241     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1990     Document Type: Article

References (49)

1. Friis-Møller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735. (Pubitemid 46658704)
2. Law MG, Friis-Moller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006; 7:218-230.
3. Neuhaus J, Jacobs DR, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.
4. + count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
5. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008; 52:569-576.
6. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005; 25:279-286. (Pubitemid 40189146)
7. Milne GL, Yin H, Brooks JD, Sanchez S, Jackson Roberts L, Morrow JD. Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol 2007; 433:113-126.
8. Morrow JD, Minton TA. Improved assay for the quantification of 11-dehydrothromboxane B2 by gas chromatography-mass spectrometry. J Chromatogr 1993; 612:179-185. (Pubitemid 23067174)
9. Murphey LJ, Williams MK, Sanchez SC, et al. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem 2004; 334:266-275. (Pubitemid 39370961)
10. Daniel VC, Minton TA, Brown NJ, Nadeau JH, Morrow JD. Simplified assay for the quantification of 2,3-dinor-6- keto-prostaglandin F1 alpha by gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl 1994; 653:117-122. (Pubitemid 24085049)
11. Schwedhelm E, Bartling A, Lenzen H, et al. Urinary 8-iso-prostaglandin F2a as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004; 109:843-848. (Pubitemid 38252735)
12. Basarici I, Altekin RE, Demir I, Yilmaz H. Associations of isoprostanes-related oxidative stress with surrogate subclinical indices and angiographic measures of atherosclerosis. Coron Artery Dis 2007; 18:615-620. (Pubitemid 351339514)
13. Martino F, Loffredo L, Carnevale R, et al. Oxidative stress is associated with arterial dysfunction and enhanced intima-media thickness in children with hypercholesterolemia: the potential role of nicotinamideadenine dinucleotide phosphate oxidase. Pediatrics 2008; 122:e648-e655.
14. McAdam BF, Byrne D, Morrow JD, Oates JA. Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation 2005; 112:1024-1029. (Pubitemid 41170271)
15. Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 1987; 76:6-14. (Pubitemid 17093187)
16. Gross ND, Boyle JO, Morrow JD, et al. Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin Cancer Res 2005; 11:6087-6093. (Pubitemid 41170341)
17. Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995; 332:1198-1203.
18. Cipollone F, Cicolini G, Bucci M. Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther 2008; 118:161-180.
19. Boger MS, Shintani A, Redhage LA, et al. Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study. J Acquir Immune Defic Syndr 2009; 52:480-487.
20. Morales CR, Terry ES, Zackert WE, Montine TJ, Morrow JD. Improved assay for the quantification of the major urinary metabolite of the isoprostane 15-F(2t)-Isoprostane (8-iso-PGF(2a)) by a stable isotope dilution mass spectrometric assay. Clin Chim Acta 2001; 314:93-99. (Pubitemid 33079187)
21. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499-511. (Pubitemid 36158056)
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
23. Dai Q, Gao YT, Shu XO, et al. Oxidative stress, obesity, and breast cancer risk: results from the Shanghai Women's Health Study. J Clin Oncol 2009; 27:2482-2488.
24. Wu X, Cai H, Xiang YB, et al. Intra-person variation of urinary biomarkers of oxidative stress and inflammation. Cancer Epidemiol Biomarkers Prev 2010; 19:947-952.
25. Rho YH, Chung CP, Oeser A, et al. Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010; 62:1473-1480.
26. Dong LM, Shu XO, Gao YT, et al. Urinary prostaglandin E2 metabolite and gastric cancer risk in the Shanghai women's health study. Cancer Epidemiol Biomarkers Prev 2009; 18:3075-3078.
27. Avalos I, Chung CP, Oeser A, et al. Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus. Lupus 2007; 16:981-986.
28. Rångemark C, Benthin G, Granstrom EF, Persson L, Winell S, Wennmalm A. Tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in women stratified by age. Circulation 1992; 86:1495-1500.
29. Wennmalm A, Benthin G, Granstrom EF, Persson L, Petersson AS, Winell S. Relation between tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in young men. Circulation 1991; 83:1698-1704.
30. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105:1650-1655. (Pubitemid 34298607)
31. Redhage LA, Shintani A, Haas DW, et al. Clinical factors associated with plasma F2-isoprostane levels in HIVinfected adults. HIV Clin Trials 2009; 10:181-192.
32. Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 2005; 39:44-54. (Pubitemid 40617018)
33. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41:661-690. (Pubitemid 32385902)
34. Davì G, Guagnano MT, Ciabattoni G, et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288:2008-2014. (Pubitemid 35204691)
35. Schoenbaum EE, Hartel D, Lo Y, et al. HIV infection, drug use, and onset of natural menopause. Clin Infect Dis 2005; 41:1517-1524. (Pubitemid 41579999)
36. Mancini F, Persico N, Genazzani AD, Volpe A, Battaglia C, De Aloysio D. Effects of hormone replacement therapy on plasma viscosity and Doppler variations in postmenopausal non-smokers and heavy smokers. Gynecol Endocrinol 2005; 20:221-226. (Pubitemid 40862909)
37. Mueck AO, Genazzani AR, Samsioe G, Vukovic-Wysocki I, Seeger H. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. Menopause 2007; 14:978-984. (Pubitemid 350098656)
38. Bayturan O, Tuzcu EM, Lavoie A, et al. The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. Arch Intern Med 2010; 170:478-484.
39. Keaney JF, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003; 23:434-439. (Pubitemid 36337219)
40. Glesby MJ, Hoover DR, Raiszadeh F, et al. Oxidant stress in HIV-infected women from the Women's Interagency HIV Study. Antivir Ther 2009; 14:763-769.
41. Jiang B, Hebert VY, Khandelwal AR, Stokes KY, Dugas TR. HIV-1 antiretrovirals induce oxidant injury and increase intima-media thickness in an atherogenic mouse model. Toxicol Lett 2009; 187:164-171.
42. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-F24.
43. Hammond E, McKinnon E, Mallal S, Nolan D. Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy. AIDS 2008; 22:2540-2543.
44. Gerschenson M, Kim C, Berzins B, et al. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother 2009; 63:1244-1250.
45. Hulgan T, Morrow J, D'Aquila RT, et al. Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin Infect Dis 2003; 37:1711-1717. (Pubitemid 37549961)
46. Flammer AJ, Hermann F, Wiesli P, et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens 2007; 25:785-791. (Pubitemid 46398873)
47. Patrignani P, Di Febbo C, Tacconelli S, et al. Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. Blood 2006; 107:3572-3574.
48. Marques-Vidal P, Mazoyer E, Bongard V, et al. Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 2002; 25:1371-1377. (Pubitemid 41071148)
49. Park K, Steffes M, Lee DH, Himes JH, Jacobs DR. Association of inflammation with worsening HOMA-insulin resistance. Diabetologia 2009; 52:2337-2344.